. Author manuscript; available in PMC: 2019 Dec 1.

Published in final edited form as: Neuropeptides. 2018 Oct 26;72:65–74. doi: 10.1016/j.npep.2018.10.003

Table 1.

Experimental design.

	Male			Female
	Icv Pretreatment	Sc Injection		Icv Pretreatment	Sc Injection
Group 1	V-Icv (n = 6)	V-Sc (n = 6)	Group 1	V-Icv (n = 6)	V-Sc (n = 6)
Group 2	V-Icv (n = 6)	INS-Sc (n = 6)	Group 2	V-Icv (n = 6)	INS-Sc (n = 6)
Group 3	MPP-Icv (n = 6)	INS-Sc (n = 6)	Group 3	MPP-Icv (n = 6)	INS-Sc (n = 6)
Group 4	PHTPP-Icv (n = 6)	INS-Sc (n = 6)	Group 4	PHTPP-Icv (n = 6)	INS-Sc (n = 6)

Icv: intracerebroventricular, INS: neutral protamine Hagedorn insulin, 10.0 U/kg bw, MPP (ERα antagonist): 11,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; 10 μM/200 nL, PHTPP (ERβ antagonist): 4-[2-phenyl-5,7-bis(triﬂuoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl] phenol; 10 μM/200 nL.